| ［1］ |
Simonetti O, Postacchini V, Offidani A. Cutaneous vasculitis and inflammatory bowel diseases［J］. G Ital Dermatol Venereol, 2015, 150（2）: 233⁃236.
|
| ［2］ |
Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflamma⁃tory bowel disease cohort［J］. Am J Gastroenterol, 2011, 106（1）: 110⁃119. DOI: 10.1038/ajg.2010.343.
|
| ［3］ |
Marzano AV, Borghi A, Stadnicki A, et al. Cutaneous manifes⁃tations in patients with inflammatory bowel diseases: pathophysio⁃logy, clinical features, and therapy［J］. Inflamm Bowel Dis, 2014, 20（1）: 213⁃227. DOI: 10.1097/01.MIB. 0000436959.62286.f9.
|
| ［4］ |
Topaloglu DF, Kocatürk E, Yorulmaz E, et al. Mucocutaneous manifestations of inflammatory bowel disease in Turkey［J］. J Cutan Med Surg, 2014, 18（6）: 397⁃404. DOI: 10.2310/7750. 2014.13209.
|
| ［5］ |
Patil SA, Cross RK. Update in the management of extraintestinal manifestations of inflammatory bowel disease［J］. Curr Gastroenterol Rep, 2013, 15（3）: 314. DOI: 10.1007/s11894⁃013⁃0314⁃8.
|
| ［6］ |
李俊霞, 田原, 王化虹, 等. 重视炎症性肠病的皮肤表现［J］. 临床荟萃, 2016, 31（8）: 847⁃851. DOI: 10.3969/j.issn.1004⁃583X. 2016.08.010.
|
| ［7］ |
De Simone C, Sollena P, Coco V, et al. Psoriasis and erythema nodosum: two comorbidities of inflammatory bowel diseases［J］. G Ital Dermatol Venereol, 2013, 148（2）: 175⁃184.
|
| ［8］ |
Ott C, Schölmerich J. Extraintestinal manifestations and compli⁃cations in IBD［J］. Nat Rev Gastroenterol Hepatol, 2013, 10（10）: 585⁃595. DOI: 10.1038/nrgastro.2013.117.
|
| ［9］ |
Carlesimo M, Abruzzese C, Narcisi A, et al. Cutaneous manifes⁃tations and gastrointestinal disorders: report of two emblematic cases［J/OL］. Clin Ter, 2015, 166（4）: e269⁃272 ［2016⁃10⁃12］. http://dx.doi.org/10.7417/T.2015.1872. DOI: 10.7417/T.2015.1872.
|
| ［10］ |
Weizman A, Huang B, Berel D, et al. Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patients［J］. Inflamm Bowel Dis, 2014, 20（3）: 525⁃533. DOI: 10.1097/01.MIB.0000442011.60285.68.
|
| ［11］ |
Ampuero J, Rojas⁃Feria M, Castro⁃Fernández M, et al. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease［J］. J Gastroenterol Hepatol, 2014, 29（2）: 291⁃295. DOI: 10.1111/jgh.12352.
|
| ［12］ |
Weizman AV, Huang B, Targan S, et al. Pyoderma gangrenosum among patients with inflammatory bowel disease: a descriptive cohort study［J］. J Cutan Med Surg, 2015, 19（2）: 125⁃131. DOI: 10.2310/7750.2014.14053.
|
| ［13］ |
Komatsu YC, Capareli GC, Boin MF, et al. Skin gangrene as an extraintestinal manifestation of inflammatory bowel disease［J］. An Bras Dermatol, 2014, 89（6）: 967⁃969. DOI: http://dx.doi.org/10.1590/abd1806⁃4841.20143001.
|
| ［14］ |
Le CL, Moguelet P, Perrin P, et al. Is topical monotherapy effective for localized pyoderma gangrenosum?［J］. Arch Dermatol, 2011, 147（1）: 101⁃103. DOI: 10.1001/archdermatol. 2010.393.
|
| ［15］ |
Bouguen G, Siproudhis L, Bretagne JF, et al. Nonfistulizing perianal Crohn′s disease: clinical features, epidemiology, and treatment［J］. Inflamm Bowel Dis, 2010, 16（8）: 1431⁃1442. DOI: 10.1002/ibd.21261.
|
| ［16］ |
Vij A, Modi GM, Suwattee P, et al. Chronic, recurrent neutro⁃philic dermatosis: a case report［J/OL］. Dermatol Online J, 2010, 16（10）: 1［2016⁃10⁃15］. https://escholarship.org/uc/item/3q7225pc.
|
| ［17］ |
Marzano AV, Ishak RS, Saibeni S, et al. Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet′s syndrome: a comprehensive review and disease classification criteria［J］. Clin Rev Allergy Immunol, 2013, 45（2）: 202⁃210. DOI: 10.1007/s12016⁃012⁃8351⁃x.
|
| ［18］ |
Binus AM, Han J, Qamar AA, et al. Associated comorbidities in psoriasis and inflammatory bowel disease［J］. J Eur Acad Dermatol Venereol, 2012, 26（5）: 644⁃650. DOI: 10.1111/j.1468⁃3083.2011.04153.x.
|
| ［19］ |
Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease［J］. Gastroenterology, 2011, 140（6）: 1704⁃1712. DOI: 10.1053/j.gastro.2011.02.046.
|
| ［20］ |
Lewis RT, Maron DJ. Efficacy and complications of surgery for Crohn′s disease［J］. Gastroenterol Hepatol （N Y）, 2010, 6（9）: 587⁃596.
|
| ［21］ |
Reddy H, Shipman AR, Wojnarowska F. Epidermolysis bullosa acquisita and inflammatory bowel disease: a review of the literature［J］. Clin Exp Dermatol, 2013, 38（3）: 225⁃229; quiz 229⁃230. DOI: 10.1111/ced.12114.
|
| ［22］ |
Marzano AV, Vezzoli P, Berti E. Skin involvement in cutaneous and systemic vasculitis［J］. Autoimmun Rev, 2013, 12（4）: 467⁃476. DOI: 10.1016/j.autrev.2012.08.005.
|
| ［23］ |
Coutzac C, Chapuis J, Poullenot F, et al. Association between infliximab trough levels and the occurrence of paradoxical manifestations in patients with inflammatory bowel disease: a case⁃control study［J］. J Crohns Colitis, 2015, 9（11）: 982⁃987. DOI: 10.1093/ecco⁃jcc/jjv159.
|
| ［24］ |
Fiorino G, Allez M, Malesci A, et al. Review article: anti TNF⁃alpha induced psoriasis in patients with inflammatory bowel disease［J］. Aliment Pharmacol Ther, 2009, 29（9）: 921⁃927. DOI: 10.1111/j.1365⁃2036.2009.03955.x.
|
| ［25］ |
Fréling E, Baumann C, Cuny JF, et al. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti⁃TNF therapy in inflammatory bowel disease: a 14⁃year experience［J］. Am J Gastroenterol, 2015, 110（8）: 1186⁃1196. DOI: 10.1038/ajg.2015.205.
|
